IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL).
Recent studies have demonstrated that rodent tumour cells engineered to secrete a variety of cytokines, or to express foreign antigens, MHC molecules or co-stimulatory molecules, are rejected by syngeneic animals. These observations have led to the initiation of a number of clinical trials using genetically modified tumour cells, to attempt to stimulate a patient anti-tumour immune response. In this study, a protocol has been developed to test in vitro the specific cytotoxic anti-tumour response generated from melanoma patient lymphocytes. The results showed that IL-12 in combination with IL-2 enhanced the autologous anti-melanoma CTL response, whereas B7.1 antigen expression on tumour cells did not increase anti-melanoma CTL generation. This method could be used to design more appropriate genetically modified tumour vaccines.
De Wit
D
D
CRC Centre for Cell and Molecular Biology, Chester Beatty Laboratories, London, UK.
Flemming
C L
CL
Harris
J D
JD
Palmer
K J
KJ
Moore
J S
JS
Gore
M E
ME
Collins
M K
MK
D018122:B7-1 Antigen / Q000502:physiology*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D018664:Interleukin-12 / Q000494:pharmacology*; D008545:Melanoma / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured
D018122:B7-1 Antigen; D018664:Interleukin-12